News Archive
- 08.12.10 - Pre-Breeding Vaccinations Set the Stage for Improved Health
- 07.27.10 - Duramune Lyme Vaccine Approved for Use in Dogs
- 06.13.10 - Bovine Respiratory Disease Takes an Economic Toll on the Herd
- 06.07.10 - Management and Vaccination Keep Trichomoniasis at Bay
- 06.01.10 - Adding to the Bottom Line with Increased Cow Comfort
- 05.10.10 - Moreaux Presented BIVI Equine Leadership Award
- 05.05.10 - Test Herd, Then Treat to Avoid Parasite Resistance
- 04.05.10 - Strong Deworming Program Pays for Itself
- 11.23.09 - New Vetera West Nile Virus Vaccines
- 11.12.09 - PROZINC™ (protamine zinc recombinant human insulin) Receives FDA Approval
- 10.26.09 - Boehringer Ingelheim Animal Health Closes Deal to Acquire a Significant Portion of the Fort Dodge Animal Health Business from Pfizer
- 10.01.09 - Mobile Dog Heart Health Tour Stopping in Central Park to Provide Free Heart Examinations
- 09.21.09 - BIVI Aquires Many of Fort Dodge's Products
- 08.17.09 - Midwest Mobile Dog Heart Health Tour to Provide Free Heart Examinations
- 08.09.09 - Boehringer Ingelheim Announces 2009 PRRS Research Award Recipients
- 08.05.09 - Swine Industry Call for PRRS Research Proposals
- 08.01.09 - BIVI Partners with EQUUS Foundation
- 05.28.09 - Swine Vets Complete Veterinary Program
- 04.27.09 - Joint Health Management Program Launched
- 03.16.09 - Mondaca Joins Swine Team
- 02.05.09 - BIVI Hires Brand Managers
- 08.11.08 - CircoFLEX-MycoFLEX Receives Approval
- 02.11.08 - Express Whole Herd Approved
- 05.02.07 - Baysinger Joins BIVI Swine Team
- 05.02.07 - Circovirus Receives Approval
- 04.08.07 - Express® FP 3 VL5 Announcement
- 04.08.07 - BIVI Recieves BVD PI Prevention Claim
News & Announcements
Express® FP 3 VL5 Offers Convenience Plus Prevention of BVD PI Calves
St. Joseph, MO (APRIL 8, 2007) – A single vaccination can now shield calves from three major viral components, as well as Lepto and Vibrio, plus prevent persistently infected (PI) calves due to BVD. Express® FP 3 VL 5 Reproductive Vaccine from Boehringer Ingelheim Vetmedica, Inc. (BIVI), is now available and reduces the number of injection sites, as well as labor costs associated with vaccination and processing.
The Express® FP/Breed-Back® FP family of vaccines is the first vaccine line ever licensed by USDA/APHIS to prevent PI calves. Challenge studies demonstrate persistent infection prevention against four BVD strains, including Types 1a, 1b, and 2.
“Express FP 3 provides a convenient combination for breeding herds that offers early onset of protection against IBR1 and BVD Type 22; and the strongest protection against PI calves on the market,” Judy Myers, Associate Director of Cattle Marketing for BIVI. “In addition to its broad coverage for major reproductive and respiratory diseases, the vaccine comes with a guarantee that covers the cost of a BVD PI calf should one be born into a herd, thereby reducing producers’ risks. Our researchers have worked hard to attain this level of protection and quality for our customers.”
The vaccine meets BQA low-dose guidelines, is administered in 2 mL SubQ doses and is available in 20 mL and 100 mL vials. More information is available at www.productionvalues.com.
1 K. Fairbanks, J. Campbell, C. Chase, et al. Rapid Onset of Protection Against Infectious Bovine Rhinotracheitis with a Modified-Live Virus Multivalent Vaccine. Veterinary Therapeutics, Volume 5, No. 11, Spring 2004.
2 K. Brock, et al. Rapidity of protection following vaccination against BVDv. BVD Control: The Future is Now Conference, January 2006.
About Boehringer Ingelheim
About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 138 affiliates in 47 countries and approximately 41,300 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
In 2008, Boehringer Ingelheim posted net sales of US $17 billion (11.6 billion euro) while spending approximately one-fifth of net sales in its largest business segment, Prescription Medicines, on research and development.
About Boehringer Ingelheim Vetmedica, Inc.
Boehringer Ingelheim Vetmedica, Inc. (St. Joseph, MO), is a subsidiary of Boehringer Ingelheim Corporation based in Ridgefield, CT and a member of the Boehringer Ingelheim group of companies.
Visit www.bi-vetmedica.com for more information.